Bioprocess refers to the process that uses living cells or their components such as bacteria and enzymes to procure desired products. The basic benefit served by the usage of single-use bioprocessing technology in the bioprocess is to reduce the cost of complex steps such as cleaning, sterilization, and maintenance of stainless steel-based bioreactor systems. The industries of biopharmaceutical and biotherapeutics depend on bioprocessing for the development and production processes. While traditionally, stainless steel equipment were used for these purposes, the high contamination rate has led to a significant increment in the use of single-use bioprocessing systems. It is a hybrid setup that is quickly gaining the attention of large and small biotechnology players. Moreover, a recent report by Transparency Market Research (TMR) has evaluated that the global single-use bio-processing systems market had an opportunity of US$2.3 bn in 2015, and estimates it to reach US$5.9 bn by the end of 2024, rising at a significant CAGR of 11.1% during the forecast period of 2016-2024.
Bioprocessing Bags Sustaining Significant Demand
In terms of product, the global single-use bioprocessing is segmented into bioreactors and fermenters, bags, bioprocess containers, mixers, tubing, filtration devices, connectors and clamps, sampling systems, and probers and sensors. Out of these, the TMR report projects that bioprocessing bags account for 27% of the share by 2024, exhibiting most robust CAGR of 14.8% during the forecast period. This surge is a reflection of frequent purchases for upstream and downstream functions such as filtration, mixing, transport, storage, and media preparation and fermentation.
By application, the market has been segmented into monoclonal antibody production, vaccine production, plant cell cultivation, patient specific cell therapies, and others including production of enzymes. According to the report, monoclonal antibody production serves the maximum demand, which is a reflection of the recent rise in the number of monoclonal antibodies in clinical trial stages. Over the past few years, the U.S. FDA and EU have approved several antibody therapeutics and are expected to continue the pattern over the course of the forecast period.
Geographically, North America and Europe currently serve the maximum demand for single-use bioprocessing systems, owing to the presence of several contract manufacturing organizations (CROs) in this region. However, Asia Pacific is anticipated to emerge as most lucrative regional market in next few years due to the booming biotechnology industry and contract research services setup made by several prominent pharmaceutical companies in the countries of India and China.
Browse the full Global Single-use Bioprocessing Systems Market report http://www.mrrse.com/single-use-bio-processing-systems-market
Highly Consolidated Competitive Landscape
The TMR report finds that five companies collectively accounted for an incredible 92.5% shares in 2015 in global single-use bioprocessing systems market. These companies are Merck KGaA, GE Healthcare, Thermo Fisher Scientific, Satorius AG, and Pall Corporation. These prominent players have a stronghold over the market with their brand identity and unique proprietary product offerings. Partnerships and collaboration is another aspect of these leading companies and consequently, the threat of new entrants in this market is highly unlikely. Broadley-James, Cellexus, Eppendorf, Finesse Solutions, Parker Hannifin, PendoTECH, Saint-Gobain, STI Components, and Tarpon Biosystems are some of the other notable players identified by the TMR report.